By Chris Wack
MEI Pharma Inc. shares were up 22%, to $3, after it and Kyowa Kirin Co. said a Phase 2 study evaluating zandelisib as a single agent for follicular lymphoma patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate as determined by Independent Review Committee assessment in the primary efficacy population.
The companies also said 35.2% of patients achieved a complete response.
The data are currently insufficiently mature to accurately estimate duration of response. In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months, median duration of follow-up in the total study population, interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%.
Patients enrolled in the study will continue to be followed for safety and duration of response.
Zandelisib is an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires